Filtered By:
Specialty: Neurology
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 3681 results found since Jan 2013.
Effectiveness of alteplase intravenous thrombolysis combined with butylphthalide in patients with acute severe cerebral infarction
CONCLUSIONS: Alteplase intravenous thrombolysis combined with butylphthalide in the treatment of severe cerebral infarction is safe, and may significantly improve patient's neurological function and quality of life without adverse reactions.PMID:36734384 | DOI:10.5114/fn.2022.118787
Source: Folia Neuropathologica - February 3, 2023 Category: Neurology Authors: Zhengqian Wang Junshuang Che Source Type: research
Predictors and long-term outcome of intracranial hemorrhage after thrombolytic therapy for acute ischemic stroke —A prospective single-center study
DiscussionOlder age, higher NIHSS, large vessel occlusion, and intra-arterial thrombolysis may correlate with ICH. The unfavorable outcome is more common in patients with ICH. Precise scoring of post-thrombolysis bleeding might be a useful tool in the evaluation of the patient's prognosis. Our findings may help to identify predictors and estimate the prognosis of ICH in patients with AIS treated with rt-PA.
Source: Frontiers in Neurology - February 1, 2023 Category: Neurology Source Type: research
Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study
Conclusion: This present study observed no difference in the efficacy and safety between biosimilar TNK and rTPA. Our findings are in concordance with published trials showing equivalence between the two molecules.
Source: Annals of Indian Academy of Neurology - January 25, 2023 Category: Neurology Authors: Ayush Mohan Snigdha Komakula Suhas Murali Pooja Anand Dyuti Shah VY Vishnu Awadh Kishor Pandit Ayush Agarwal Deepti Vibha Mamta Bhushan Singh MV Padma Srivastava Rohit Bhatia Source Type: research
Early high-dose intravenous immunoglobulin for refractory heparin-induced thrombocytopenia with stroke: Two case reports
Heparin-induced thrombocytopenia (HIT) is a drug reaction caused by anti-platelet factor 4 (PF4)/heparin antibodies of the IgG class that activate through Fc γ receptors on platelets and monocytes. They consume platelets and increase thrombin generation.1 HIT occurs 5 to 14 days after the start of heparinization.2 Management of HIT involves discontinuing heparin and switching to an alternative anticoagulant to prevent thrombosis and normalize platelet l evels.3–5 Autoimmune HIT (aHIT), which maintains marked heparin-independent platelet activation even after discontinuing heparin, has recently attracted attention.
Source: Journal of Stroke and Cerebrovascular Diseases - January 24, 2023 Category: Neurology Authors: Naoki Makita, Tomoyuki Ohara, Yukiko Tsuji, Tetsuhiro Ueda, Takuma Nakamura, Toshiki Mizuno, Masahiro Makino Tags: Case Report Source Type: research
S100b in acute ischemic stroke clots is a biomarker for post-thrombectomy intracranial hemorrhages
ConclusionsHigher S100b expression in AIS clots, higher NIHSS at admission and higher number of passes during thrombectomy are all associated with PTIH. Further investigation of S100b expression in AIS clots by neutrophils, macrophages and T-lymphocytes could provide insight into the role of S100b in thromboinflammation.
Source: Frontiers in Neurology - January 23, 2023 Category: Neurology Source Type: research
Recombinant tissue plasminogen activator (rTPA) management for first onset acute Ischemic Stroke with covid -19 and non-covid -19 patients
In this study we compare the efficacy and safety of Tissue plasminogen activator (rTPA) in acute ischemic stroke (AIS) patients with or without Covid-19 infection.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2023 Category: Neurology Authors: Eman M Khedr, Ahmed Abdelwarith, Gehad M Moussa, Mostafa Saber Source Type: research
Pre- and in-hospital delays in the use of thrombolytic therapy for patients with acute ischemic stroke in rural and urban Egypt
ConclusionThe limited availability of stroke-ready hospitals in rural Egypt leads to delays in stroke management, with subsequent treatment inequality of rural patients with acute stroke.
Source: Frontiers in Neurology - January 20, 2023 Category: Neurology Source Type: research
